Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Tony Gordon, Murali Prahalad


Genesis Genetics has appointed Tony Gordon to be laboratory director for its UK operations and vice president of its US operations. In his new roles, Gordon will sign off on all patient reports in the UK and will help expand the company's testing operations in the country.

Gordon joins Detroit-based Genesis Genetics from BlueGnome. Genesis Genetics relies on BlueGnome's 24sure array comparative genomic hybridization platform in its preimplantation genetic diagnostic services, according to its website.

Murali Prahalad has been named president and CEO of Epic Sciences, a La Jolla, Calif.-based company developing microfluidic chip-based tests that isolate and characterize circulating tumor cells.

Prahalad joins Epic from Life Technologies, where he was vice president of corporate strategy. He also served as vice president of business development at Sequenom and as an analyst for Gemini Consulting in Tokyo.

In addition to English, Prahalad speaks Japanese, French, and Kannada, a language spoken in India, Epic said.

Prahalad holds a PhD in biochemistry and molecular pharmacology from Harvard University, and a BSc in cellular and molecular biology from the University of Michigan.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.